StockNews.AI
SVRA
StockNews.AI
83 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA

1. Savara is under investigation for alleged securities fraud. 2. The FDA rejected Savara's application for MOLBREEVI, impacting stock price. 3. Savara's stock dropped 31.69% to $1.94 on this news. 4. Pomerantz LLP is seeking investors for potential class action. 5. Historical context shows severe impacts from similar FDA rejections.

3m saved
Insight
Article

FAQ

Why Very Bearish?

Savara's significant stock drop indicates strong negative investor sentiment after FDA rejection.

How important is it?

The article details a critical FDA rejection and ongoing legal issues, severely impacting SVRA's stock.

Why Short Term?

The core issue affecting SVRA's price is immediate; ongoing investigations may increase volatility.

Related Companies

FGENCTMXSGMO
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Savara and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 27, 2025, Savara issued a press release “announc[ing] that the Company received [a refusal to file] letter from the FDA for the [Biologics License Application] of MOLBREEVI as a therapy to treat patients with autoimmune PAP.”  On this news, Savara’s stock price fell $0.90 per share, or 31.69%, to close at $1.94 per share on May 27, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News